Sillajen Biotherapeutics (215600) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The companys pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment of primary liver cancer. It also develops JX929, a chemosensitizing oncolytic immunotherapy that eradicates cancer; activates chemotherapy in cancer tissue; administers as a monotherapy to patients with breast, colorectal, and pancreatic cancer; and treats melanoma and metastatic colon cancer. The company operates in South Korea and the US. Sillajen is headquartered in Busan, South Korea.

Sillajen Biotherapeutics (215600) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Medivate Partners Invests in SillaJen 10
Partnerships 11
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
Equity Offering 14
SillaJen Plans to Raise Funds in IPO 14
Debt Offering 15
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
Acquisition 16
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics - Key Competitors 19
Sillajen Biotherapeutics - Key Employees 20
Sillajen Biotherapeutics - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product News 22
04/12/2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial 22
Clinical Trials 23
Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List Of Tables


Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medivate Partners Invests in SillaJen 10
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
SillaJen Plans to Raise Funds in IPO 14
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics, Key Competitors 19
Sillajen Biotherapeutics, Key Employees 20
Sillajen Biotherapeutics, Other Locations 21
Sillajen Biotherapeutics, Subsidiaries 21

List Of Figures


Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Sillajen Biotherapeutics (215600) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The companys pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic

USD 250 View Report

Sillajen Biotherapeutics (215600) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The companys pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic

USD 250 View Report

Sillajen Biotherapeutics (215600) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The companys pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic

USD 250 View Report

Sillajen Biotherapeutics - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sillajen Biotherapeutics (SillaJen), formerly SillaJen, Inc. is a biotechnology company that designs and develops multi-functional immunotherapeutics for cancer. The companys first pipeline product Pexa-Vec, is an oncolytic immunotherapeutic virus, administered

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available